Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Lancet Oncol. 2020 Mar 11;21(4):551–560. doi: 10.1016/S1470-2045(20)30060-7

Table 2:

Dose escalation and response to cycle 1

Dose level Venetoclax Cytarabine Idarubicin N MRD neg CR CRi PR NR
1 240 mg/m2 (max 400 mg) 100 mg/m2 q12h × 20 doses 0 7 2 (29%) 1 (14%) 2 (29%) 1 (14%) 3 (43%)
2a 360 mg/m2 (max 600 mg) 100 mg/m2 q12h × 20 doses 0 5 0 0 1 (20%) 1 (20%) 3 (60%)
2b 240 mg/m2 (max 400 mg) 1000 mg/m2 q12h × 8 doses 0 3 1 (33%) 2 (66%) 0 0 1 (33%)
3 360 mg/m2 (max 600 mg) 1000 mg/m2 q12h × 8 doses 0 11 7 (64%) 7 (64%) 1 (9%) 1 (9%) 2 (18%)
4 360 mg/m2 (max 600 mg) 1000 mg/m2 q12h × 8 doses 12 mg/m2 9 3 (33%) 6 (67%) 0 1 (11%) 2 (22%)

N, evaluable patients; MRD neg, minimal residual disease negative (<0.1%) among patients obtaining a CR or CRi; CR, complete response; CRi, complete response with incomplete hematological recovery; PR, partial response; NR, no response

Note that MRD Negative patients are a subset of CR/CRi patients and not a discrete group.